Please login to the form below

Not currently logged in
Email:
Password:

Autoimmune disorders

This page shows the latest Autoimmune disorders news and features for those working in and with pharma, biotech and healthcare.

Amgen plans acquisition of Rodeo Therapeutics

Amgen plans acquisition of Rodeo Therapeutics

Earlier this year, Amgen also entered into a licence and collaboration agreement with Evoq Therapeutics to develop novel drugs for autoimmune disorders. ... Under the terms of the deal, Amgen will gain exclusive rights to ‘selected’ autoimmune

Latest news

  • Amgen strikes $240m autoimmune deal with Evoq Therapeutics Amgen strikes $240m autoimmune deal with Evoq Therapeutics

    Companies will collaborate on novel drugs for autoimmune disorders. Amgen has entered into a license and collaboration agreement with Evoq Therapeutics worth over $240m, with the aim of developing novel drugs ... for autoimmune disorders.

  • J&J inks $6.5bn all-cash deal to acquire Momenta J&J inks $6.5bn all-cash deal to acquire Momenta

    Johnson &Johnson (J&J) has entered a definitive agreement to acquire Momenta, a US-based biotech specialising in treatments for hard-to-treat autoimmune diseases. ... The drug is also being evaluated in a phase 2/3 study as a treatment for warm

  • FDA clears wider use for Boehringer’s Ofev in lung disease FDA clears wider use for Boehringer’s Ofev in lung disease

    rare autoimmune disease that affects around 100, 000 people in the US. ... The new label applies to between 18% and 32% of patients with around 200 separate disorders, including  “unclassifiable ILDs, autoimmune ILDs, chronic hypersensitivity

  • Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

    The side effects include cardiovascular disorders and immune-related disorders. Lemtrada is now restricted for use only in the treatment of relapsing-remitting MS if the disease is highly active, despite ... It is also restricted for use by patients with

  • UK immunology biotech MiroBio launches with $34m fundraising UK immunology biotech MiroBio launches with $34m fundraising

    Will develop therapeutic antibodies for autoimmune diseases. A new UK start-up called MiroBio has come out of stealth mode with a £27m ($34m) in first-round financing for its antibody ... therapies for autoimmune and inflammatory disorders.

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    Sanofi. Exclusive worldwide licence. INX-021, a pc CD40L mAb in autoimmune disorders.

  • Deal Watch November 2016 Deal Watch November 2016

    autoimmune disorders, such as rheumatoid arthritis. ... acquisition - company. 235. Idera Pharmaceuticals/ Vivelix Pharmaceuticals. IMO-9200, antagonist of TLR 7, 8 and 9, for non-malignant GI disorders (p1) back ups.

  • Deal Watch September 2016 Deal Watch September 2016

    as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis. ... 210. Ligand / Seelos. Licence. 4 programmes including aplindore for CNS disorders.

  • Reaching new heights Reaching new heights

    Disease treatments in 2020 will be transformed by the increased number and quality of new drugs in clusters of innovation around cancer, hepatitis C, autoimmune disorders, heart disease and an array

  • Deal Watch March 2016 Deal Watch March 2016

    Padlock's technology targets autoimmune disorders with protein/peptidyl arginine deiminase (PAD) inhibitors and offers the potential to prevent disease development in patients with early stage disease. ... Acquisition - company. $600. Boehringer Ingelheim

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....